Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,272 Million (Small Cap)
19.00
NA
4.53%
0.21
17.22%
3.15
Revenue and Profits:
Net Sales:
419 Million
(Quarterly Results - Sep 2025)
Net Profit:
99 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.89%
0%
-5.89%
6 Months
-6.63%
0%
-6.63%
1 Year
5.11%
0%
5.11%
2 Years
-3.34%
0%
-3.34%
3 Years
-7.2%
0%
-7.2%
4 Years
67.97%
0%
67.97%
5 Years
103.42%
0%
103.42%
Hunan Fangsheng Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.01%
EBIT Growth (5y)
29.24%
EBIT to Interest (avg)
7.84
Debt to EBITDA (avg)
1.56
Net Debt to Equity (avg)
0.27
Sales to Capital Employed (avg)
0.74
Tax Ratio
11.54%
Dividend Payout Ratio
42.98%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.65%
ROE (avg)
12.21%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
3.24
EV to EBIT
22.15
EV to EBITDA
16.56
EV to Capital Employed
2.75
EV to Sales
3.45
PEG Ratio
0.55
Dividend Yield
3.72%
ROCE (Latest)
12.41%
ROE (Latest)
17.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
419.10
416.20
0.70%
Operating Profit (PBDIT) excl Other Income
81.90
99.00
-17.27%
Interest
3.50
3.70
-5.41%
Exceptional Items
0.00
0.00
Consolidate Net Profit
98.90
77.80
27.12%
Operating Profit Margin (Excl OI)
195.30%
184.90%
1.04%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 0.70% vs -0.45% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 27.12% vs -12.29% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,761.10
1,613.20
9.17%
Operating Profit (PBDIT) excl Other Income
324.10
243.10
33.32%
Interest
22.10
21.50
2.79%
Exceptional Items
-11.50
-2.40
-379.17%
Consolidate Net Profit
249.80
179.60
39.09%
Operating Profit Margin (Excl OI)
135.80%
100.40%
3.54%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 9.17% vs -9.13% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 39.09% vs -35.09% in Dec 2023
About Hunan Fangsheng Pharmaceutical Co., Ltd. 
Hunan Fangsheng Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






